3 recruiting, 2 completed, 1 enrolling by invitation, 1 not yet recruiting. 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Depression Bipolar: new trials by email Literature Review of Depression Bipolar trials Research Report on Depression Bipolar
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Longitudinal Study on the Sustainability of Transcranial Magnetic Stimulation Protocols - Biomarkers Repetitive transcranial magnetic stimulation - Depression - Major Depressive Disorder, Depression Bipolar | Recruiting | Hospital Center Guillaume Régnier | 30 | 2026-06-04 | 2026-07-06 | |
| Right-sided 1-Hz Repetitive Transcranial Magnetic Stimulation (rTMS) Versus Left-sided Intermittent Theta Burst Stimulation (iTBS) in Patients With Depression repetitive transcranial magnetic stimulation, intermittent theta burst stimulation - Depression - Major Depressive Disorder, Depression Bipolar | Phase 4 | Recruiting | Region Örebro County | 350 | 2025-12-15 | 2025-12-16 |
| Mental Health Mission Mood Disorder Cohort Study Depression - Major Depressive Disorder, Depression Bipolar | Not yet recruiting | University of Oxford | 2000 | 2025-10-01 | 2025-10-03 | |
| Digital Phenotypes for Predicting Depression Depression - Major Depressive Disorder, Depression Bipolar | Enrolling by invitation | Korea University Anam Hospital | 540 | 2025-02-27 | 2025-09-03 | |
| Precision Subclassification of Mental Health in Diabetes: Digital Twins for Precision Mental Health to Track Subgroups Diabetes (DM), Diabete Mellitus | Recruiting | Forschungsinstitut der Diabetes Akademie Mergentheim | 1809 | 2025-01-01 | 2025-12-04 | |
| Magnetic Resonance Spectroscopy (MRS) in Midlife Depression Depression, Depression Bipolar | Completed | Emory University | 169 | 2016-07-01 | 2023-02-03 | |
| Study Evaluating Bifeprunox in Bipolar Depression Bifeprunox - Depression Bipolar | Phase 3 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 380 | 2005-06-01 | 2007-12-05 |
Bipolar Disorder (7) · Depression (3) · Inflammation (2) · Anorexia Nervosa (1) · Anxiety Disorders (1) · Binge-Eating Disorder (1) · Bulimia Nervosa (1) · Consciousness Disorders (1) · Depressive Disorder, Major (1) · Depressive Disorder, Treatment-Resistant (1) · Diabetes Complications (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Disordered Eating Behavior (1) · Feeding and Eating Disorders (1)
Bipolar and Related Disorders (7) · Mental Disorders (7) · Mood Disorders (6) · Behavior (3) · Behavioral Symptoms (3) · Pathological Conditions, Signs and Symptoms (3) · Depressive Disorder (2) · Pathologic Processes (2) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Metabolic Diseases (1) · Nervous System Diseases (1) · Neurobehavioral Manifestations (1) · Neurocognitive Disorders (1) · Neurologic Manifestations (1)
Transcranial Magnetic Stimulation (2) · bifeprunox (1)
Emory University (1) · Forschungsinstitut der Diabetes Akademie Mergentheim (1) · Hospital Center Guillaume Régnier (1) · Korea University Anam Hospital (1) · Region Örebro County (1) · University of Oxford (1) · Wyeth is now a wholly owned subsidiary of Pfizer (1)
United States (2) · France (1) · Germany (1) · South Korea (1) · Sweden (1) · United Kingdom (1)
Ebrahim Haroon, MD (1) · Heon-Jeong Lee, Professor (1)
R01MH107033 (1)